The macrolides: Erythromycin, clarithromycin, and azithromycin

Mayo Clinic Proceedings

Volumn 74, Issue 6, 1999, Pages 613-634

  Alvarez Elcoro, Salvador ^a,b   Enzler, Mark J ^a  

^a MAYO CLINIC   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIAL INFECTION; CONFERENCE PAPER; DOSE CALCULATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG STRUCTURE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MYCOBACTERIUM AVIUM; OTOTOXICITY; PATIENT COMPLIANCE; STREPTOCOCCUS PNEUMONIAE; TREATMENT INDICATION;

EID: 0033022048     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/74.6.613     Document Type: Conference Paper

References (346)

1. Franklin TJ, Snow GA. Biochemistry of Antimicrobial Action. 3rd ed. London: Chapman & Hall; 1981
2. Pestka S. Inhibitors of protein synthesis. In: Weissbach H, Pestka S, editors. Molecular Mechanisms of Protein Biosynthesis. New York: Academic Press; 1977. p 467
3. Oleinick NL The erythromycins. In: Corcoran JW, Hahn FE, editors. Mechanism of Action of Antimicrobial and Antitumor Agents. New York: Springer-Verlag; 1975. pp 396-419
4. Mazzei T, Mini E, Novell! A, Periti P. Chemistry and mode of action of macrolides. J Antimicrob Chemother 1993;31(Suppl C):l-9
5. Kirst HA. Semi-synthetic derivatives of erythromycin. Prog Med Chem 1993:30:57-88
6. Fernandes PB, Hardy DJ. Comparative in vitro potencies of nine new macrolides. Drugs Exp Clin Res 1988;14:445-451
7. Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics [published erratum appears in Clin Pharm 1992;11:308]. Clin Pharm 1992:11:137-152
8. Barry AL, Jones RN, Thornsberry C. In vitro activities of azithromycin (CP 62,993), Clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. Antimicrob Agents Chemother 1988:32:752-754
9. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Fourth Edition-Approved Standard. Villanova (PA): NCCLS; 1997 (Publication No. NCCLS M7-A4)
10. Hardy DJ, Hensey DM, Beyer JM, Vojtko C, McDonald EJ, Fernandes PB. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob Agents Chemother 1988:32:1710-1719
11. Barry AL, Fuchs PC, Brown SD. Relative potencies of azithromycin, clarithromycin and five other orally administered antibiotics [letter]. J Antimicrob Chemother 1995;35:552-555
12. Van Asselt GJ, Sloos JH, Mouton RP, Van Boven CP, Van de Klundert JA. Susceptibility of Streptococcus pyogenes to azithromycin, clarithromycin, erythromycin and roxithromycin in vitro. J Med Microbiol 1995;43:386-391
13. Barry AL, Pfaller MA, Fuchs PC, Packer RR. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993. Antimicrob Agents Chemother 1994:38:2419-2425
14. Thomson KS, Chartrand SA, Sanders CC, Block SL Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae. Antimicrob Agents Chemother 1997:41:478-480
15. Fass RJ. Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance. Antimicrob Agents Chemother 1993:37:2080-2086
16. Delmee M, Carpentier M, Glupczynski Y, Gordts B, Magerman K, Simon A, et al. In vitro susceptibilities of 180 clinical isolates of Haemophilus influenzae to ampicillin, amoxycillin/clavulanate, cefaclor, cefuroxime, cefotaxime, clarithromycin, and azithromycin. Acta Clin Belg 1996:51:237-243
17. Neu HC, Chin NX, Saha G, Labthavikul P. Comparative in vitro activity of the new oral macrolide azithromycin. Eur J Clin Microbiol Infect Dis 1988:7:541-544
18. Goldstein EJ, Nesbit CA, Citron DM. Comparative in vitro activities of azithromycin, Bay y 3118, levofloxacin, sparfloxacin, and 11 other oral antimicrobial agents against 194 aerobic and anaerobic bite wound isolates. Antimicrob Agents Chemother 1995:39:10971100
19. Pajukanta R, Asikainen S, Saarela M, Alaluusua S, JousimiesSomer H. In vitro activity of azithromycin compared with that of erythromycin against Actinobacillus actinomycetemcomitans. Antimicrob Agents Chemother 1992:36:1241-1243
20. Renaudin H, Bebear C. Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum. EurJ Clin Microbiol Infect Dis 1990:9:838-841
21. Ishida K, Kaku M, Irifune K, Mizukane R, Takemura H, Yoshida R, et al. In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae. Antimicrob Agents Chemother 1994:38:790-798
22. Nimmo GR, Bull JZ. Comparative susceptibility of Legionella pneumophila and Legionella longbeachae to 12 antimicrobial agents. J Antimicrob Chemother 1995:36:219-223
23. Welsh L, Gaydos C, Quinn TC. In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae. Antimicrob Agents Chemother 1996: 40:212-214
24. Mehaffey PC, Putnam SD, Barrett MS, Jones RN. Evaluation of in vitro spectra of activity of azithromycin, clarithromycin, and erythromycin tested against strains of Neisseria gonorrhoeae by reference agar dilution, disk diffusion, and Etest methods. J Clin Microbiol 1996:34:479-481
25. Lefevre JC, Escaffre MC, Courdil M, Lareng MB. In vitro evaluation of activities of azithromycin, clarithromycin and sparfloxacin against Chlamydia trachomatis. Pathol Biol (Paris) 1993;41:313-315
26. Slaney L, Chubb H, Ronald A, Brunham R. In-vitro activity of azithromycin, erythromycin, ciprofloxacin and norfloxacin against Neisseria gonorrhoeae, Haemophilus ducreyi, and Chlamydia trachomatis. J Antimicrob Chemother 1990;25(Suppl A): 1-5
27. Rylander M, Hallander HO. In vitro comparison of the activity of doxycycline, tetracycline, erythromycin and a new macrolide, CP 62993, against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum. Scand J Infect Dis Suppl 1988;53:12-17
28. Jones BM, Kinghorn GR, Duerden Bl. In vitro activity of azithromycin and erythromycin against organisms associated with bacterial vaginosis and chancroid. Eur J Clin Microbiol Infect Dis 1988; 7:551-553
29. Retsema J, Girard A, Schelkly W, Manousos M, Anderson M, Bright G, et al. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother 1987; 31:1939-1947
30. Rautelin H, Renkonen 0V, Kosunen TU. Azithromycin resistance in Campylobacter jejuni and Campylobacter coli. Eur J Clin Microbiol Infect Dis 1993;12:864-865
31. Gordillo ME, Singh KV, Murray BE. In vitro activity of azithromycm against bacterial enteric pathogens. Antimicrob Agents Chemother 1993:37:1203-1205
32. Metchock B. In-vitro activity of azithromycin compared with other macrolides and oral antibiotics against Salmonella typhi. J Antimicrob Chemother 1990;25(Suppl A):29-31
33. Naik S, Ruck R. In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. Antimicrob Agents Chemother 1989;33:1614-1616
34. Inderlied CB, Kemper CA, Bermudez LE. The Mycobacterium avium complex. Clin Microbiol Rev 1993:6:266-310
35. Rapp RP, McCraney SA, Goodman NL, Shaddick DJ. New macrolide antibiotics: usefulness in infections caused by mycobacteria other than Mycobacterium tuberculosis. Ann Pharmacother 1994;28: 1255-1263
36. Brown BA, Wallace RJ Jr, Onyi GO, De Rosas V, Wallace RJ III. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. c/ie/onae-like organisms. Antimicrob Agents Chemother 1992:36:180-184
37. Dever LL, Jorgensen JH, Barbour AG. Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi. Antimicrob Agents Chemother 1993;37:1704-1706
38. Preac-Mursic V, Wilske B, Schierz G, Suss E, Gross B. Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi. Eur J Clin Microbiol Infect Dis 1989;8:651-653
39. Mursic VP, Wilske B, Schierz G, Holmburger M, Suss E. In vitro and in vivo susceptibility of Borrelia burgdorferi. Eur J Clin Microbiol 1987:6:424-426
40. McNulty ÇA, Dent JC. Susceptibility of clinical isolates of Campylobacter pylori to twenty-one antimicrobial agents. Eur J Clin Microbiol Infect Dis 1988;7:566-569
41. Linares J, Garau J, Dominguez C, Ferez JL. Antibiotic resistance and serotypes of Streptococcus pneumoniae from patients with community-acquired pneumococcal disease. Antimicrob Agents Chemother 1983:23:545-547
42. Seppälä H, Nissinen A, Järvinen H, Huovinen S, Henriksson T, Herva E, et al. Resistance to erythromycin in group A streptococci. N Engl J Med 1992:326:292-297
43. Vanhoof R, Gordts B, Dierickx R, Coignau H, Butzler JP. Bacterio static and bactericidal activities of 24 antimicrobial agents against Campylobacter fetus subsp. jejuni. Antimicrob Agents Chemother 1980:18:118-121
44. Bechtol LD, Stephens VC, Pugh CT, Perkal MB, Coletta PA. Erythromycin esters-comparative in-vivo hydrolysis and bioavailability. Curr Ther-Res Clin Exp 1976:20:610-622
45. Griffith RS, Black HR. Comparison of the blood levels obtained after single and multiple doses of erythromycin estolate and erythromycin stéarate. Am J Med Sei 1964;247:69-74
46. Osono T, Umezawa H. Pharmacokinetics of macrolides, lincosamides and streptogramins. J Antimicrob Chemother 1985; 16(Suppl A):151-166
47. Philipson A, Sabath LD, Charles D. Transplacental passage of erythromycin and clindamycin. N Engl J Med 1973:288:1219-1221
48. Anders BJ, Lauer BA, Paisley JW, Relier LB. Double-blind placebo controlled trial of erythromycin for treatment of Campylobacter enteritis. Lancet 1982:1:131-132
49. Medical Letter. Handbook of Antimicrobial Therapy. New Rochelle (NY): Medical Letter on Drugs and Therapeutics; 1992
50. Dajani AS, Taubert KA, Wilson W, Böiger AF, Bayer A, Ferrieri P, et al. Prevention of bacterial endocarditis: recommendations by the American Heart Association. JAMA 1997:277:1794-1801
51. Centers for Disease Control and Prevention. 1998 guidelines for treatment of sexually transmitted diseases. MMWR Morb Mortal Wkly Rep 1998;47{RR-1):1-111
52. Tolman KG, Sannella JJ, Freston JW. Chemical structure of erythromycin and hepatotoxicity. Ann Intern Med 1974;81:58-60
53. Haydon RC, Thelin JW, Davis WE. Erythromycin ototoxicity: analysis and conclusions based on 22 case reports. Otolaryngol Head Neck Surg 1984:92:678-684
54. Swanson DJ, Sung RJ, Fine MJ, Orloff JJ, Chu SY, Yu VL. Erythromy ein ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am J Med 1992:92:61-68
55. Schoenenberger RA, Haefeli WE, Weiss P, Ritz RF. Association of intravenous erythromycin and potentially fatal ventricular tachycardia with Q-T prolongation (torsades de pointes). BMJ 1990;300:13751376
56. Reisz G, Pingleton SK, Melethil S, Ryan PB. The effect of erythromycin on fheophylline pharmacokinetics in chronic bronchitis. Am Rev RespirDis 1983:127:581-584
57. Bachmann K, Schwartz Jl, Forney R Jr, Frogameni A, Jauregui LE. The effect of erythromycin on the disposition kinetics of warfarin. Pharmacology 1984:28:171-176
58. Wong YY, Ludden TM, Bell RD. Effect of erythromycin on carbamazepine kinetics. Clin Pharmacol Ther 1983:33:460-464
59. Martell R, Heinrichs D, Stiller CR, Jenner M, Keown PA, Dupre J. The effects of erythromycin in patients treated with cyclosporine. Ann Intern Med 1986:104:660-661
60. Bahal N, Nahata MC. The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann Pharmacother 1992:26:46-55
61. Kakegawa T, Ogawa T, Hirose S. Mode of inhibition of protein synthesis by TE-031 (A-56268). Chemotherapy 1988;36(Suppl 3):123-128
62. Kakegawa T, Hirose S. Mode of inhibition of protein synthesis by metabolites of clarithromycin. Chemotherapy 1990:38:317-323
63. Hardy DJ, Swanson RN, Rode RA, Marsh K, Shipkowitz NL, Clement JJ. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother 1990:34:1407-1413
64. Dabernat H, Delmas C, Seguy M, Fourtillan JB, Girault J, Lareng MB. The activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus inf/uenzae, determined by in-vitro and serum bactericidal tests. J Antimicrob Chemother 1991;27(Suppl A}:19-30
65. Garrison MW, Malone CL, Eiland J, Anderson DE. Influence of pH on the antimicrobial activity of clarithromycin and 14-hydroxyclarithromycin against Haemophilus influenzae using an in vitro pharmacodynamic model. Diagn Microbiol Infect Dis 1997;27:139-145
66. Ives TJ, Manzewitsch P, Regnery RL, Butts JD, Kebede M. In vitro susceptibilities of Bartonella henselae, B. quintana, B. elizabethae, Rickettsia rickettsii, R. conorii, R. akari, and R. prowazekii to macrolide antibiotics as determined by immunofluorescent-antibody analysis of infected Vero cell monolayers. Antimicrob Agents Chemother 1997;41:578-582
67. Agacifidan A, Moncada J, Schachter J. In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother 1993; 37:1746-1748
68. Neu HC. The development of macrolides: clarithromycin in perspective. J Antimicrob Chemother 1991;27(Suppl A): 1-9
69. Fernandes PB, Bailer R, Swanson R, Hanson CW, McDonald E, Ramer N, et al. In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrob Agents Chemother 1986:30:865-873
70. Washington JA. A multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract pathogens in the United States, 1992-1994: the Alexander Project. Diagn Microbiol Infect Dis 1996:25:183-190
71. Anderson R, Joone G, van Rensburg CE. An in-vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A56268, TE-031), a new macrolide antimicrobial agent. J Antimicrob Chemother 1988:22:923-933
72. Felmingham D, Robbins MJ, Sanghrajka M, Leakey A, Ridgway GL. The in vitro activity of some 14-, 15- and 16-membered macrolides against Staphylococcus spp., Legionella spp., Mycoplasma spp. and Ureaplasma urealyticum. Drugs Exp Clin Res 1991:17:91-99
73. Segreti J, Meyer P, Kapeil K. In vitro activity of macrolides against intracellular Legionella pneumophila. Diagn Microbioi Infect Dis 1996:25:123-126
74. Pontani D, Washton H, Bouchillon S, Johnson J. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin. Eur J Clin Microbiol Infect Dis 1998:17:413-419
75. Thornsberry C, Ogilvie P, Kahn J, Mauriz Y (Laboratory Investigator Group). Surveillance of antimicrobial resistance 'in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. Diagn Microbiol Infect Dis 1997:29:249-257
76. Block SL. Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media. Pediatr Infect Dis J 1997;16:449-456
77. Hoogkamp-Korstanje JA, Dirks-Go SI, Kabel P, Manson WL, Stobberingh EE, Vreede RW, et al. Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin. J Antimicrob Chemother 1997; 39:411-414
78. Doern GV. Brueggemann AB, Pierce G, Hogan T, Holley HP Jr, Rauch A. Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996:40:2884-2886
79. Traub WH, Leonhard B. Susceptibility of Moraxella catarrhalis to 21 antimicrobial drugs: validity of current NCCLS criteria for the interpretation of agar disk diffusion antibiograms. Chemotherapy 1997:43:159-167
80. Berk SL, Kalbfleisch JH (Alexander Project Collaborative Group). Antibiotic susceptibility patterns of community-acquired respiratory isolates of Moraxella catarrhalis in western Europe and in the USA. J Antimicrob Chemother 1996;38(Suppl A):85-96
81. Stauffer F, Dortbudak 0, Lahonik E. In vitro testing of clarithromycin in combination with ethambutol and rifampicin against Mycobacterium avium complex. Infection 1991;19:343-345
82. Rastogi N, Labrousse V. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. Antimicrob Agents Chemother 1991;35:462-470
83. Derouin F, Chastang C. Activity in vitro against Toxoplasmagondiiol azithromycin and clarithromycin alone and with pyrimethamine [letter], J Antimicrob Chemother 1990:25:708-711
84. Araujo FG, Prokocimer P, Lin T, Remington JS. Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis. Antimicrob Agents Chemother 1992:36:2454-2457
85. Alder J, Mitten M, Jarvis K, Gupta P, Clement J. Efficacy of clarithromycin for treatment of experimental Lyme disease in vivo. Antimicrob Agents Chemother 1993:37:1329-1333
86. Peters DH, Clissold SP. Clarithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992:44:117-164
87. Le Be l M. Comparative pharmacokinetics of new macrolides. Can J Infect Dis 1993:4:149-151
88. Chu S, Park Y, Locke C, Wilson DS, Cavanaugh JC. Drug-food interaction potential of clarithromycin. a new macrolide antimicrobial. J Clin Pharmacol 1992:32:32-36
89. Chu SY, Deaton R, Cavanaugh J. Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob Agents Chemother 1992:36:1147-1150
90. Eisenberg E, Barza M. Azithromycin and clarithromycin. Curr Clin Top Infect Dis 1994;14:52-79
91. Hardy DJ, Guay DR, Jones RN. Clarithromycin, a unique macrolide: a pharmacokinetic, microbiological, and clinical overview. Diagn Microbiol Infect Dis 1992:15:39-53
92. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25(Suppl A):73-82
93. Ferrero JL, Bopp BA, Marsh KC, Quigley SC, Johnson MJ, Anderson DJ.etal. Metabolism and disposition of clarithromycin in man. Drug Metab Dispos 1990:18:441-446
94. Periti P, Mazzei T, Mini E, Novell! A. Pharmacokinetic drug interactions of macrolides [published erratum appears in Clin Pharmncokinet 1993:24:70). Clin Pharmacokinet 1992:23:106131
95. Bergogne-Bérézin E. Tissue distribution of dirithromycin: comparison with erythromycin. J Antimicrob Chemother 1993;31(Suppl C):77-87
96. Yakatan GJ, Rasmussen CE, Feis PJ, Wallen S. Bioinequivalence of erythromycin ethylsuccinate and enteric-coated erythromycin pellets following multiple oral doses. J Clin Pharmacol 1985:25:36-42
97. Rutland J, Berend N, Mariin GE. The influence of food on the bioavailability of new formulations of erythromycin stéarate and base. Br J Clin Pharmacol 1979:8:343-347
98. Wildfeuer A, Laufen H, Leitold M, Zimmermann T. Comparison of the pharmacokinetics of three-day and five-day regimens of azithromycin in plasma and urine. J Antimicrob Chemother 1993; 31(Suppl E):51-56
99. Thakker KM, Caridi F, Powell M, Chung M. Multiple dose pharmacokinetics of azithromycin following 1 hour intravenous infusions in hospitalized patients with community acquired pneumonia [abstract]. Program Abstr Intersci Conf Antimicrob Agents Chemother 1997:37:24
100. Davey PG. The pharmacokinetics of clarithromycin and its 14-OH metabolite. J Hosp Infect 1991;19(Suppl A):29-37
101. Chu SY, Granneman GR, Pichotta PJ, Decourt JP, Girault J, Fourtillan JB. Effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics. J Clin Pharmacol 1993:33:480485
102. Andersen G, Esmonde TS, Coles S, Macklin J, Carnegie C. A comparative safety and efficacy study of clarithromycin and erythromycin stéarate in community-acquired pneumonia. J Antimicrob Chemother 1991;27(Suppl A):117-124
103. Hamedani P, AM J, Hafeez S, Bachand R Jr, Dawood G, Quereshi S, et al. The safety and efficacy of clarithromycin in patients with Legionella pneumonia. Chest 1991;100:1503-1506
104. Scaglione F. Comparison of the clinical and bacteriological efficacy of clarithromycin and erythromycin in the treatment of streptococcal pharyngitis. Curr Med Res Opin 1990:12:25-33
105. Levenstein JH. Clarithromycin versus penicillin in the treatment of streptococcal pharyngitis. J Antimicrob Chemother 1991;27(Suppl A):67-74
106. Bachand RT Jr. A comparative study of clarithromycin and penicillin VK in the treatment of outpatients with streptococcal pharyngitis. J Antimicrob Chemother 1991;27(Suppl A):75-82
107. March! E. Comparative efficacy and tolerability of clarithromycin and amoxycillin in the treatment of out-patients with acute maxillary sinusitis. Curr Med Res Opin 1990:12:19-24
108. Langtry HD, Brogden RN. Clarithromycin: a review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients. Drugs 1997:53:973-1004
109. Bachand RT Jr. Comparative study of clarithromycin and ampicillin in the treatment of patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1991;27(Suppl A):91100
110. O'Neill SJ, Millar ED, Coles SJ, Bachand RT. Safety and efficacy of clarithromycin in the treatment of acute mild to moderate respiratory tract infections. Ir Med J 1991:84:33-35
111. Chien SM, Pichotta P, Siepman N, Chan CK. Treatment of commu nity acquired pneumonia: a randomized controlled trial comparing clarithromycin (CM) and erythromycin (EM) [abstract]. Program Abstr Intersci Conf Antimicrob Agents Chemother 1991;31:244
112. Chien SM, Pichotta P, Siepman N, Chan CK (Canada-Sweden Clarithromycin-Pneumonia Study Group). Treatment of community acquired pneumonia: a multicenter, double-blind, randomized study comparing clarithromycin with erythromycin. Chest 1993:103:697-701
113. Neu HC, Chick TW. Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections. Chest 1993:104:1393-1399
114. Adam D. Clarithromycin 250 mg b.i.d. for 5 or 10 days in the treatment of adult patients with purulent bronchitis. Infection 1993:21:265-271
115. Northcutt VJ, Craft JC, Pichotta P. Safety and efficacy of clarithromycin (C) compared to erythromycin (E) in the treatment (Tx) of bacterial skin or skin structure infections (SSSIs) [abstract]. Program Abstr Intersci Conf Antimicrob Agents Chemother 1990: 30:309
116. Millikan L, Coleman E, Bopp B, Northcutt VJ. Safety and efficacy of clarithromycin (C) compared to cefadroxil (CEF) in the treatment of mild to moderate bacterial skin or skin structure infections (SSSIs) [abstract]. Program Abstr Intersci Conf Antimicrob Agents Chemother 1990:30:309
117. Parish LC (Clarithromycin Study Group). Clarithromycin in the treatment of skin and skin structure infections: two multicenter clinical studies. Int J Dermatol 1993;32:528-532
118. Gupta S, Siepman H. Comparative safety and efficacy of clarithromycin vs standard agents in the treatment of mild to moderate bacterial skin or skin structure infections [abstract]. In: Proceedings and Abstracts of the First International Conference on the Macrolides, Azalides, and Streptogramins; 1992; Santa Fe (NM)
119. Hebert AA, Still JG, Reuman PD. Comparative safety and efficacy of clarithromycin and cefadroxil suspensions in the treatment of mild to moderate skin and skin structure infections in children. Pediatr Infect Dis J 1993;12(Suppl 3):S112-S117
120. Jones JL, Hanson DL, Chu SY, Fleming PL, Hu DJ, Ward JW (Adult/ Adolescent Spectrum of HIV Disease Project Group). Surveillance of AIDS-defining conditions in the United States. AIDS 1994; 8:1489-1493
121. Dautzenberg B, Truffot C, Legris S, Meyohas MC, Berlie HC, Mercat A, et al. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome: a controlled clinical trial. Am Rev Respir Dis 1991; 144:564-569
122. Dautzenberg B, Saint Marc T, Meyohas MC, Eliaszewitch M, Haniez F, Rogues AM, et al. Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome. Arch Intern Med 1993:153:368-372
123. Chaisson RE, Benson CA, Dube MP, Heifets LB, Korvick JA, Elkin S, et al (AIDS Clinical Trials Group Protocol 157 Study Team). Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med 1994;121:905-911
124. Benson CA, Ellner JJ. Mycobacterium avium complex infection and AIDS: advances in theory and practice. Clin Infect Dis 1993;17:7-20
125. Shafran SD, Singer J, Zarowny DP, Phillips P, Salit I, Walmsley SL, et al (Canadian HIV Trials Network Protocol 010 Study Group). A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and Clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N EnglJ Med 1996;335:377-383
126. Chaisson RE, Keiser P, Pierce M, Fessel WJ, Ruskin J, Lahart C, et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS 1997:11:311-317
127. Cohn DL, Fisher E, Franchino B, Hodges J, Chestnut J, Child C, et al. Comparison of two doses of Clarithromycin in a randomized trial of four 3-drug regimens for treatment of disseminated Mycobacterium avium complex disease in AIDS: excess mortality associated with high-dose Clarithromycin [abstract]. IntConfAIDS 1996;ll(Program Suppl):27
128. Dautzenberg B, Truffot-Pernot C, Hazebroucq J, Legris S, Guerin C, Begelman C, et al. A randomized comparison of two Clarithromycin doses for treatment of Mycobacterium avium complex infections. Infection 1997;25:16-21
129. Centers for Disease Control and Prevention. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex for adults and adolescents infected with human immunodeficiency virus: U.S. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. MMWR Morb Mortal WklyRep 1993;42(RR-9):14-20
130. Kaplan JE, Masur H, Holmes KK, Wilfert CM, Sperling R, Baker SA, et al (USPHS/IDSA Prevention of Opportunistic Infections Working Group). USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: an overview. Clin Infect Dis 1995;21(Suppl 1):S12-S31
131. Ostroff SM, Spiegel RA, Feinberg J, Benson CA, Horsburgh CR Jr. Preventing disseminated Mycobacterium avium complex disease in patients infected with human immunodeficiency virus. Clin Infect Dis 1995;21(Suppl 1):S72-S76
132. Ward TT, Rimland D, Kauffman C, Huycke M, Evans TG, Heifets L (Veterans HIV Research Consortium). Randomized, open-label trial of azithromycin plus ethambutol vs. Clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Clin Infect Dis 1998:27:1278-1285
133. Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT, Onyi GO, et al. Initial Clarithromycin monotherapy for Mycobacterium avium-intracetlulare complex lung disease. Am J Respir Crit Care Med 1994;149:1335-1341
134. Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first 50 patients. Am J Respir Crit Care Med 1996; 153:1766-1772
135. Pierce M, Crampton S, Henry D, Heifets L, LaMarca A, Montecalvo M, et al. A randomized trial of Clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996:335:384-391
136. Datri 001 Study Group. Clarithromycin (CL) plus rifabutin (RFB) for MAC prophylaxis: evidence for a drug interaction [abstract]. Natl ConfHum Retroviruses Re/at Infect 1993;1:106
137. Freedberg KA, Cohen CJ, Barber TW. Prophylaxis for disseminated Mycobacterium avium complex (MAC) infection in patients with AIDS: a cost-effectiveness analysis. J Acquir Immune Defic Syndr Hum Retrovirol 1997:15:275-282
138. 3 [abstract]. Conf Retro Opportun Infect 1996;3:91
139. Heifets LB. Clarithromycin against Mycobacterium avium complex infections. Tuber Lung Dis 1996;77:19-26
140. Bordet AL, Machet L, De Muret A, Francois-Ramanantsoa C, Lorette G, Vaillant L. Mycobacterium chelonae cutaneous infection: efficacy of prolonged treatment by Clarithromycin. Ann Dermatol Venereol 1997:124:251-253
141. van Aarem A, Muytjens HL, Smits MM, Cremers CW. Recurrent therapy resistant mastoiditis by Mycobacterium chelonae abscessus, a nontuberculous Mycobacterium. Int J Pediatr Otorhinolaryngol 1998;43:61-72
142. Tartaglione T. Treatment of nontuberculous mycobacterial infections: role of clarithromycin and azithromycin. din Ther 1997;19: 626-638
143. Saluja A, Peters NT, Lowe L, Johnson TM. A surgical wound infection due to Mycobacterium chelonae successfully treated with clarithromycin. Dermatol Surg 1997;23:539-543
144. Klapper SR, Patrinely JR, Kaplan SL, Font RL. Atypical mycobacte rial infection of the orbit. Ophthalmology 1995;102:1536-1541
145. Engelhardt E, Feldmann R, Skaria A, Salomon D. Postoperative infection with Mycobacterium chelonae. Hautarzt 1996;47:863-866
146. Forslund T, Rummukainen M, Kousa M, Krees R, Relander A, Katila ML. Disseminated cutaneous infection due to Mycobacterium chelonae in a patient with rheumatoid arthritis, amyloidosis, and renal failure. Nephrol Dial Transplant 1995;10:1234-1236
147. Mushatt DM, Witzig RS. Successful treatment of Mycobacterium abscessus infections with multidrug regimens containing clarithromycin [letter]. Clin Infect Dis 1995;20:1441-1442
148. Butt AA. Cervical adenitis due to Mycobacterium fortuitum in patients with acquired immunodeficiency syndrome. Am J Med Sei 1998:315:50-55
149. Franzblau SG, Hastings RC. In vitro and in vivo activities of macrolides against Mycobacterium leprae. Antimicrob Agents Chemother 1988:32:1758-1762
150. Ji B, Jamet P, Perani EG, Bobin P, Grosset JH. Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy. J Infect Dis 1993:168:188-190
151. Chan GP, Garcia-lgnacio BY, Chavez VE, Livelo JB, Jimenez CL, Parrilla ML, et al. Clinical trial of clarithromycin for lepromatous leprosy. Antimicrob Agents Chemother 1994:38:515-517
152. Banerjee DK, McDermott-Lancaster RD, McKenzie S. Experimental evaluation of possible new short-term drug regimens for treatment of multibacillary leprosy. Antimicrob Agents Chemother 1997:41:326330
153. Ji B, Jamet P, Perani EG, Sow S, Lienhardt C, Petinon C, et al. Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. Antimicrob Agents Chemother 1996:40:2137-2141
154. Graham DY, Opekun AR, Klein PD. Clarithromycin for the eradication of Helicobacter pylori. J Clin Gastroenterol 1993;16:292-294
155. European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori infection: the Maastricht Consensus Report. Gut 1997;41:8-13
156. Syngal S, Wolfe MM, Friedman LS, Van Dam J. Helicobacter pylori: pathogenic factor in the etiology of gastric diseases. Infect Dis Clin Pract 1997:6:17-27
157. Peterson WL, Graham DY, Marshall B, Baiser MJ, Genta RM, Klein PD, et al. Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. Am J Gastroenterol 1993:88:1860-1864
158. Thijs JC, Van Zwet AA, Moolenaar W, Oom JA, De Körte H, Runhaar EA. Short report: clarithromycin, an alternative to metronidazole in the triple therapy of Helicobacter pylori infection. Aliment Pharmacol Ther 1994;8:131-134
159. Markham A, McTavish D. Clarithromycin and omeprazole as Helicobacter
160. Logan RP, Gummett PA, Schaufelberger HD, Greaves RR, Mendelson GM, Walker MM, et al. Eradication of Helicobacter pylori with clarithromycin and omeprazole. Gut 1994:35:323-326
161. Lazzaroni M, Bargiggia S, Porro GB. Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter py/ori-associated duodenal ulcer. Am J Gastroenterol 1997:92:649-652
162. Barza M, Eisenberg E. Clarithromycin and azithromycin. Infect Dis Clin Pract 1996;5:291-302
163. Lacassin F, Schaffe D, Perronne C, Longuet P, Leport C, Vilde JL. Clarithromycin-minocycline combination as salvage therapy for toxoplasmosis in patients infected with human immunodeficiency virus [letter]. Antimicrob Agents Chemother 1995;39:276-277
164. Fernandez-Martin J, Leport C, Morlat P, Meyohas MC, Chauvin JP, Vilde JL. Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS. Antimicrob Agents Chemother 1991:35:2049-2052
165. Raffi F, Struillou L, Ninin E, Reliquat V, Billaud E, Milpied B. Breakthrough cerebral toxoplasmosis in patients with AIDS who are being treated with clarithromycin [letter]. Clin Infect Dis 1995:20:1076-1077
166. Watkins MS, Polk RE, Stotka JL. Drug interactions of macrolides: emphasis on dirithromycin. Ann Pharmacother 1997;31:349-356
167. Bass JW, Vincent JM, Person DA. The expanding spectrum of Bartonella infections. II. Cat-scratch disease. Pediatr Infect Dis J 1997:16:163-179
168. Dattwyler RJ, Grunwaldt E, Luft BJ. Clarithromycin in treatment of early Lyme disease: a pilot study. Antimicrob Agents Chemother 1996;40:468-469
169. Quay DR, Patterson DR, Seipman N, Craft JC. Overview of the tolerability profile of Clarithromycin in preclinical and clinical trials. Drug Saf 1993:8:350-364
170. Yew WW, Chau CH, Lee J, Leung CW. Cholestatic hepatitis in a patient who received Clarithromycin therapy for a Mycobacterium cheionae lung infection [letter]. Clin Infect Dis 1994;18:1025-1026
171. Shaheen N, Grimm IS. Fulminant hepatic failure associated with Clarithromycin. Am J Gastmenterol 1996;91:394-395
172. Liviu L, Yair L, Yehuda S. Pancreatitis induced by Clarithromycin [letter]. Ann Intern Med 1996:125:701
173. Pijpers E, van Rijswijk RE, Takx-Kohlen B, Schrey G. A clarithromycin-induced myasthénie syndrome. Clin Infect Dis 1996:22:175-176
174. Wallace RJ Jr, Brown BA, Griffith DE. Drug intolerance to high-dose Clarithromycin among elderly patients. Diagn Micmbiol Infect Dis 1993:16:215-221
175. Polis MA, Haneiwich S, Kovacs JA, Davey RT, Walker RE, Falloon J, et al. Dose escalation study to determine the safety, maximally tolerated dose (MTD), and pharmacokinetics of Clarithromycin (clari) with zidovudine (zdv) in HIV-infected persons [abstract]. Program Abstr Intersci Conf Antimicrob Agents Chemother 1991;31:138
176. Schlossberg D. Azithromycin and Clarithromycin. Med Clin North Am 1995 Jul;79:803-815
177. Ludden TM. Pharmacokinetic interactions of the macrolide antibiotics. Clin Pharmacokinet 1985:10:63-79
178. Nawarskas JJ, McCarthy DM, Spinler SA. Digoxin toxicity secondary to Clarithromycin therapy. Ann Pharmacother 1997:31:864-866
179. Spicer ST, Liddle C, Chapman JR, Barclay P, Nankivell BJ, Thomas P, et al. The mechanism of cyclosporine toxicity induced by Clarithromycin. Br J Clin Pharmacol 1997;43:194-196
180. Brown BA, Wallace RJ Jr, Griffith DE, Warden R. Clarithromycinassociated digoxin toxicity in the elderly. Clin Infect Dis 1997; 24:92-93
181. Paar D, Terjung B, Sauerbruch T. Life-threatening interaction between Clarithromycin and disopyramide [letter]. Lancet 1997; 349:326-327
182. Grau E, Real E, Pastor E. Interaction between Clarithromycin and oral anticoagulants [letter], Ann Pharmacother 1996:30:14951496
183. Gillum JG, Israel DS, Scott RB, Climo MW, Polk RE. Effect of combination therapy with ciprofloxacin and Clarithromycin on theophylline pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother 1996;40:1715-1716
184. Bedford TA, Rowbotham DJ. Cisapride: drug interactions of clinical significance [published erratum appears in Drug Saf 1997:17:196]. DrugSaf 1996:15:167-175
185. Yeates RA, Laufen H, Zimmermann T. Interaction between rnidazolam and Clarithromycin: comparison with azithromycin. Int J Clin Pharmacol Ther 1996:34:400-405
186. Sketris IS, Wright MR, West ML. Possible role of the intestinal P450 enzyme system in a cyclosporine-clarithromycin interaction. Pharmacotherapy 1996;16:301-305
187. Vance E, Watson-Bitar M, Gustavson L, Kazanjian P. Pharmacokinetics of Clarithromycin and zidovudine in patients with AIDS. Antimicrob Agents Chemother 1995:39:1355-1360
188. Gustavson LE, Chu SY, Mackenthun A, Gupta SD, Craft JC. Drug interaction between Clarithromycin and oral zidovudine in HIV-1 infected patients [abstract]. Clin Pharmacol Ther 1993:53:163
189. Vance E, Guzman J, Bitar M, Kazanjian P. Clarithromycin and zidovudine pharmacokinetic study [abstract]. Int Conf AIDS 1994:10:201
190. Polis MA, Piscitelli SC, Vogel S, Witebsky FG, Conville PS, Petty B, et al. Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997:41:1709-1714
191. Gillum JG, Bruzzese VL, Israel DS, Kaplowitz LG, Polk RE. Effect of Clarithromycin on the pharmacokinetics of 2',3'-dideoxyinosine in patients who are seropositive for human immunodeficiency virus. Clin Infect Dis 1996:22:716-718
192. Mor N, Heifets L. MICs and MBCs of Clarithromycin against Mycobacterium avium within human macrophages. Antimicrob Agents Chemother 1993:37:111-114
193. Mor N, Heifets L. Inhibition of intracellular growth of Mycobacterium avium by one pulsed exposure of infected macrophages to clarithromycin. Antimicrob Agents Chemother 1993:37:1380-1382
194. Heifets LB, Lindholm-Levy PJ, Comstock RD. Clarithromycin mini mal inhibitory and bactericidal concentrations against Mycobacterium avium. Am Rev Respir Dis 1992:145:856-858
195. Gelber RH, Siu P, Tsang M, Murray LP. Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice. Antimicrob Agents Chemother 1991;35:760-763
196. Ji B, Perani EG, Grosset JH. Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice. Antimicrob Agents Chemother 1991:35:579-581
197. Fiese EF, Steffen SH. Comparison of the acid stability of azithromycin and erythromycin A. J Antimicrob Chemother 1990;25(Suppl A):39-47
198. Cooper MA, Nye K, Andrews JM, Wise R. The pharmacokinetics and inflammatory fluid penetration of orally administered azithromycin. J Antimicrob Chemother 1990:26:533-538
199. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989:33:277-282
200. Coates P, Daniel R, Houston AC, Antrobus JH, Taylor T. An open study to compare the pharmacokinetics, safety and tolerability of a multiple-dose regimen of azithromycin in young and elderly volunteers. Eur J Clin Microbiol Infect Dis 1991;10:850-852
201. Nahata MC, Koranyi Kl, Gadgil SD, Hilligoss DM, Fouda HG, Gardner MJ. Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension. Antimicrob Agents Chemother 1993:37:314-316
202. Foulds G, Luke DR, Teng R, Willavize SA, Friedman H, Curatolo WJ. The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension. J Antimicrob Chemother 1996;37(Suppl C):37-44
203. Jaruratanasirikul S, Hortiwakul R, Tantisarasart T, Phuenpathom N, Tussanasunthornwong S. Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. Antimicrob Agents Chemother 1996:40:825-826
204. Lode H, Borner K, Koeppe P, Schaberg T. Azithromycin-review of key chemical, pharmacokinetic and microbiological features. J Antimicrob Chemother 1996;37(Suppl C):l-8
205. Mazzei T, Surrenti C, Novell! A, Crispo A, Fallani S, Caria V, et al. Pharmacokinetics of azithromycin in patients with impaired hepatic function. J Antimicrob Chemother 1993;31(Suppl E):57-63
206. Amsden GW. Macrolides versus azalides: a drug interaction update. Ann Pharmacother 1995:29:906-917
207. Felstead S. Azithromycin drug interactions. Pathol Biol (Paris) 1995:43:512-514
208. Amsden GW. Review of the drug interaction profile of azithromycin [abstract]. In: Proceedings and Abstracts of the Second International Conference on the Macrolides, Azalides, and Streptogramins; 1994 Jan 19-22; Venice (Italy)
209. Gardner MJ, Coates PE, Hilligoss DM, et al. Lack of effect of azithromycin on pharmacokinetics of theophylline in man [abstract]. In: Proceedings of the VIII Mediterranean Congress of Chemotherapy, 1992 May 24-29; Athens (Greece)
210. Zimmermann T, Yeates RA, Laufen H, Scharpf F, Leitold M, Wildfeuer A. Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. Arzneimittelforschung 1996:46:213-217
211. Honig PK, Wortham DC, Zamani K, Cantilena LR. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest 1994;7:148-156
212. Harris S, Hilligoss DM, Colangelo PM, Eller M, Okerholm R. Azithromycin and terfenadine: lack of drug interaction. Clin Pharmacol Ther 1995;58:310-315
213. Chave JP, Munafo A, Chatton JY, Dayer P, Glauser MP, Biollaz J. Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. Antimicrob Agents Chemother 1992:36:1013-1018
214. Foulds G, Hilligoss DM, Henry EB, Gerber N. The effects of an antacid or cimetidine on the serum concentrations of azithromycin. J Clin Pharmacol 1991;31:164-167
215. Treadway G, Pontani D. Paediatric safety of azithromycin: worldwide experience. J Antimicrob Chemother 1996;37(Suppl C):143-149
216. Pacifico L, Scopetti F, Ranucci A, Pataracchia M, Savignoni F, Chiesa C. Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children. Antimicrob Agents Chemother 1996;40: 1005-1008
217. O'Doherty B (Paediatric Azithromycin Study Group). Azithromycin versus penicillin V in the treatment of paediatric patients with acute streptococcal pharyngitis/tonsillitis. Eur J Clin Microbiol Infect Dis 1996:15:718-724
218. Still JG. Azithromycin suspension vs penicillin suspension in treatment of children with streptococcal pharyngitis [abstract]. Clin ' Pharmacol Ther 1993;53:195
219. Still JG. Management of pédiatrie patients with group A betahemolytic Streptococcus pharyngitis: treatment options. Pediatr Infect Dis J 1995;14(Suppl):S57-S6l
220. Still JG. Treatment of streptococcal pharyngitis in children With five days of azithromycin suspension [abstract]. Program Abstr Intersci Conf Antimicrob Agents Chemother 1994:34:120
221. Pichichero ME. Therapeutic considerations for'-management of otitis media, sinusitis, and tonsillopharyngitis. Pediatr Asthma Allergy Immunol 1992;6:167;174
222. McCarty JM. Bacterial susceptibility and tympanocentesis in acute otitis media. Pediatr Infect.Dis J 1995;14(Suppl):S45-S50
223. Me Li n n S,'Williams D. Incidence of antibiotic-resistant Streptococcus pneumoniae and beta-lactamase-positive Haemophilus influenzae in clinical isolates from patients with otitis media. Pediatr Infect Dis J 1996;15(Suppl):S3-S9
224. Mohs E, Rodriguez-Solares A, Rivas E, el Hoshy Z. A comparative study of azithromycin and amoxycillin in paediatric patients with acute otitis media. J Antimicrob Chemother 1993;31(Suppl E):73-79
225. Aronovitz G. A multicenter, open label trial of azithromycin vs. amoxicillin/clavulanate for the management of acute otitis media in children. Pediatr Infect Dis J 1996;15(Suppl):S15-S19
226. Daniel RR. Comparison of azithromycin and co-amoxiclav in the treatment of otitis media in children. J Antimicrob Chemother 1993; 31(Suppl E):65-71
227. Khurana CM. Issues concerning antibiotic use in child care settings. Pediatr Infect Dis J 1995;14(Suppl):S34-S38
228. Khurana CM. A multicenter, randomized, open label-comparison of azithromycin and amoxicillin/clavulanate in acute otitis media among children attending day care or school. Pediatr Infect Dis J 1996;15(Suppl):S24-S29 - .
229. McLinn S. A multicenter, double blind comparison of azithromycin and amoxicillin/clavulanate for the treatment of acute otitis media in children. Pediatr Infect Dis J 1996;15(Suppl):S20-S23
230. Principi N. Multicentre comparative study of the efficacy and safety of azithromycin compared with amoxicillin/clavulanic acid in the treatment of paediatric patients with otitis media. Eur J Clin Microbio/Infect Dis 1995:14:669-676
231. Schaad UB. Multicentre evaluation of azithromycin in comparison with co-amoxiclav for the treatment of acute otitis media in children. J Antimicrob Chemother 1993;31(Suppl E):81-88
232. Rodriguez AF. An open study to compare azithromycin with cefaclor in the treatment of children with acute otitis media. J Antiniicrob Chemother 1996;37(Suppl C):63-69
233. Dagan R, Leibovitz E, Jacobs M, Fliss D, Leiberman A, Yagupsky P. Bactériologie response to acute otitis media caused by Haemophilus influenzae treated with azithromycin [abstract]. Program Abstr Intersci Conf Antimicrob Agents Chemother 1997;37:345
234. Roord JJ, Wolf BH, Gossens MM, Kimpen JL. Prospective open randomized study comparing efficacies and safeties of a 3-day course of azithromycin and a 10-day course of erythromycin in children with community-acquired acute lower respiratory tract infections. Antimicrob Agents Chemother 1996:40:2765-2768
235. Arguedas A, Rodriguez A, Loaiza C, Urruela R, Rodriguez F, Bartlett H, et al. Azithromycin vs amox/clav in pédiatrie community-acquired LRTIs. Infect Med 1997;14:807-809; 813-814
236. Harris J, Campbell M, Kolokathis A (Pédiatrie Pneumonia Study Group). Safety and efficacy of azithromycin in the treatment of community acquired pneumonia in children [abstract]. Program Abstr Intersci Conf Antimicrob Agents Chemother 1996:36:286
237. Montera L A comparative study of the efficacy, safety and tolerability of azithromycin and cefaclor in the treatment of children with acute skin and/or soft tissue infections. J Antimicrob Chemother 1996;37(Suppl C):125-131
238. Rodriguez-Solares A, Perez-Gutierrez F, Prosper! J, Milgram E, Martin A. A comparative study of the efficacy, safety and tolerance of azithromycin, dicloxacillin and flucloxacillin in the treatment of children with acute skin and skin-structure infections. J Antimicrob Chemother 1993;31(Suppl E):103-109
239. Johnson RB. The role of azalide antibiotics in the treatment of Chlamydia. Am J Obstet Gynecol 1991;164:1794-1796
240. Steingrimsson 0, Olafsson JH, Thorarinsson H, Ryan RW, Johnson RB, Tilton RC. Azithromycin in the treatment of sexually transmitted .disease. J Antimicrob Chemother 1990;25(Suppl A):109-114
241. Lassus A. Comparative studies of azithromycin in skin and soft-tissue infections and sexually transmitted infections by Neisseria and Chlamydia species. J Antimicrob Chemother 1990;25(Suppl A):115-121
242. Martin DH, Mroczkowski TF, Dalu ZA, McCarty J, Jones RB, Hopkins SJ, et al (Azithromycin for Chlamydial Infections Study Group). A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. N Engl J Med 1992:327:921-925
243. Hammerschlag MR, Golden NH, Oh MK, Gelling M, Sturdevant M, Brown PR, et al. Single dose of azithromycin for the treatment of -genital chlamydial infections in adolescents. J Pediatr 1993:122:961-965
244. Whatley JD, Thin RN, Mumtaz G, Ridgway GL, et al. Azithromycin vs doxycycline in the treatment of non-gonococcal urethritis. Int J STD AIDS 1991:2:248-251
245. Ossewaarde JM, Plantema FH, Rieffe M, Nawrocki RP, de Vries A, van Loon AM. Efficacy of single-dose azithromycin versus doxycycline in the treatment of cervical infections caused by Chlamydia trachomatis. EurJ Clin Microbiol Infect Dis 1992:11:693-697
246. Nilsen A, Halsos A, Johansen A, Hansen E, Torud E, Moseng D, et al. A double blind study of single dose azithromycin and doxycycline in the treatment of chlamydial urethritis in mâles. Genitourin Med 1992:68:325-327
247. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med 1991;91(Suppl 3A):40S-45S
248. Nuovo J, Melnikow J, Paliescheskey M, King J, Mowers R. Costeffectiveness analysis of five different antibiotic regimens for the treatment of uncomplicated Chlamydia trachomatis cervicitis. J Am Board Fain Pract 1995:8:7-16
249. Magid D, Douglas JM Jr, Schwartz JS. Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis. Ann Intern Med 1996:124:389-399
250. Haddix AC, Hillis SD, Kassler WJ. The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women. Sex Transm Dis 1995:22:274-280
251. Edwards M, Rainwater K, Carter S, Williamson F. Comparison of azithromycin and erythromycin for Chlamydia cervicitis in pregnancy [abstract]. Am J Obstet Gynecol 1994:170:419
252. Bush MR, Rosa C. Azithromycin and erythromycin in the treatment of cervical chlamydial infection during pregnancy. Obstet Gynecol 1994;84:6t63
253. Lauharanta J, Saarinen K, Mustonen MT, Happonen HP. Single dose oral azithromycin versus seven-day doxycycline in the treatment of non-gonococcal urethritis in males. J Antimicrob Chemother 1993;31(Suppl E):177-183
254. Lister PJ, Balechandran T, Ridgway GL, Robinson AJ. Comparison of azithromycin and doxycycline in the treatment of non-gonococcal urethritis in men. J Antimicrob Chemother 1993;31(Suppl E):185-192
255. Stamm WE, Hicks CB, Martin DH, Leone P, Hook EW III, Cooper RH, et al. Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men: a randomized double-blind study. JAMA 1995:274:545-549
256. Intravenous azithromycin [product monograph]. New York: Pfizer; 1997
257. Waugh MA. Open study of the safety and efficacy of a single oral dose of azithromycin for the treatment of uncomplicated gonorrhoea in men and women. J Antimicrob Chemother 1993;31(Suppl E):193-198
258. Steingrimsson 0, Olafsson JH, Thorarinsson H, Ryan RW, Johnson RB, Tilton RC. Single dose azithromycin treatment of gonorrhea and infections caused by C. trachomatis and U. urealyticum in men. Sex Transm Dis 1994:21:43-46
259. Handsfield HH, Dalu ZA, Martin DH, Douglas JM Jr, McCarty JM, Schlossberg D (Azithromycin Gonorrhea Study Group). Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Sex Transm Dis 1994:21:107-111
260. Lukehart SA, Föhn MJ, Baker-Zander SA. Efficacy of azithromycin for therapy of active syphilis in the rabbit model. J Antimicrob Chemother 1990;25(Suppl A):91-99
261. Verdon MS, Handsfield HH, Johnson RB. Pilot study of azithromycin for treatment of primary and secondary syphilis. Clin Infect Dis 1994:19:486-488
262. Mashkilleyson AL, Gomberg MA, Kutin SA, et al. Azithromycin in early syphilis [abstract]. In: Proceedings and Abstracts of the Second International Conference on the Macrolides, Azalides, and Streptogramins; 1994 Jan 19-22; Venice (Italy), p 73
263. Issoire C, Casin I, Perenet F, et al. Pilot study of azithromycin in the treatment of chancroid caused by Haemophilus ducreyi [abstract]. In: Program and Abstracts of the First Conference on Infectious Diseases; 1990; Montreal (Canada)
264. Tyndall MW, Agoki E, Plummer FA, Malisa W, Ndinya-Achola JO, Ronald AR. Single dose azithromycin for the treatment of chancroid: a randomized comparison with erythromycin. Sex Transm Dis 1994:21:231-234
265. Martin DH, Sargent SJ, Wendel GD Jr, McCormack WM, Spier NA, Johnson RB. Comparison of azithromycin and ceftriaxone for the treatment of chancroid. Clin Infect Dis 1995;21:409-414
266. Ballard RC, Ye H, Matta A, Dangor Y, Radebe F. Treatment of chancroid with azithromycin. Int J STD AIDS 1996;7(Suppl 1):9-12
267. Bowden FJ, Mein J, Plunkett C, Bastian I. Pilot study of azithromycin in the treatment of genital donovanosis. Genitourin Med 1996:72:17-19
268. Amin NM, Breadon G. An open-label, noncomparative study to evaluate the efficacy, safety, and tolerability of azithromycin in the treatment of patients with acute sinusitis. Clin Ther 1995:17:701707
269. Hayle R, Lingaas E, Hoivik HO, Odegard T. Efficacy and safety of azithromycin versus phenoxymethylpenicillin in the treatment of acute maxillary sinusitis. Eur J Clin Microbiol Infect Dis 1996:15: 849-853
270. Felstead SJ, Daniel R (European Azithromycin Study Group). Short course treatment of sinusitis and other upper respiratory tract infections with azithromycin: a comparison with erythromycin and " amoxycillin. J Int Med Res 1991:19:363-372
271. Hooton TM. A comparison of azithromycin and penicillin V for the treatment of streptococcal pharyngitis. Am J Med 1991;91(Suppl 3A):23S-26S
272. Daniel R (European Azithromycin Study Group). Simplified treatment of acute lower respiratory tract infection with azithromycin: a comparison with erythromycin and amoxycillin. J Int Med Res 1991:19:373-383
273. Dark D. Multicenter evaluation of azithromycin and cefaclor in acute lower respiratory tract infections. Am J Med 1991;91(Suppl 3A):31S-35S
274. Kinasewitz G, Wood RG. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia. Eur J Clin Microbio/ Infect Dis 1991:10:872-877
275. Balmes P, Clerc G, Dupont B, Labram C, Pariente R, Poirier R. Comparative study of azithromycin and amoxicillin/clavulanic acid in the treatment of lower respiratory tract infections. Eur J Clin Microbiol Infect Dis 1991;10:437-439
276. Hoepelman AI, Sips AP, van Helmond JL, van Barneveld PW, Neve AJ, Zwinkels M, et al. A single-blind comparison of three-day azithromycin and ten^day co-amoxiclav treatment of acute lower respiratory tract infections. J Antimicrob Chemother 1993:31(Suppl E):147-152
277. Bradbury F. Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection. J Antimicrob Chemother 1993;31(Suppl E):153-162
278. Laurent K. Efficacy, safety and tolerability of azithromycin versus roxithromycin in the treatment of acute lower respiratory tract infections. J Antimicrob Chemother 1996;37(Suppl C):115-124
279. Gray GC, McPhate DC, Leinonen M, Cassell GH, Deperalta EP, Putnam SD, et al. Weekly oral azithromycin as prophylaxis for agents causing acute respiratory disease. Clin Infect Dis 1998:26: 103-110
280. Hammerschlag MR, Gregory WW, Schwartz DB, Pistorius BJ, Inverse A, Kolokathis A. Azithromycin in the treatment of community-acquired pneumonia due to Chlamydia pneumoniae [abstract]. Program Abstr Intersci Conf Antimicrob Agents Chemother 1997; 37:352
281. Daniel R (European Azithromycin Study Group). Azithromycin, eryth romycin and cloxacillin in the treatment of infections of skin and associated soft tissues. J Int Med Res 1991;19:433-445
282. Kiani R. Double-blind, double-dummy comparison of azithromycin and cephalexin in the treatment of skin and skin structure infections. Eur J Clin Microbiol Infect Dis 1991;10:880-884
283. Mallory SB. Azithromycin compared with cephalexin in the treatment of skin and skin structure infections. Am J Med 1991;91(Suppl 3A):36S-39S
284. Amaya-Tapia G, Aguirre-Avalos G, Andrade-Villanueva J, PeredoGonzalez G, Morfin-Otero R, Esparza-Ahumada S, et al. Once-daily azithromycin in the treatment of adult skin and skin-structure infections. J Antimicrob Chemother 1993;31(Suppl E):129-135
285. Iseman MD. Mycobacterium avium complex and the normal host: the other side of the coin [editorial]. N Engl J Med 1989:321:896-898
286. Young LS, Wiviott L, Wu M, Kolonoski P, Bolan R, Inderlied CB. Azithromycin for treatment of Mycobacterium avium-intraceliulare complex infection in-patients with AIDS. Lancet 1991;338:1107-1109
287. Berry A, Koletar S, Williams D. Azithromycin therapy for disseminated Mycobacterium avium-intracellulare in AIDS patients [abstract]. Natl Conf Hum Retroviruses Relat Infect 1993;1:106
288. Husson RN, Ross LA, Sandelli S, Inderlied CB, Venzon D, Lewis LL, et al. Orally administered clarithromycin for the treatment of systemic Mycobacterium avium complex infection in children with acquired immunodefi'ciency 'syndrome. J Pediatr 1994;124:807-814
289. Horsburgh CR Jr. Advances in the prevention and treatment of Mycobacterium avium disease [editorial]. N Engl J Med 1996:335: 428-430
290. Masur H (Public Health Service Task Force on.Prophylaxis and Therapy for Mycobacteriurti avium Complex). Recommendations on prophylaxis and therapy Tor disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. N Engl J Med 1993;329:898-904
291. Nightingale SD, Cameron DW, Gordin FM, Sullam PM, Cohn DL, Chaisson fcE, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993:329:828-833
292. Havlir DV, Dubé MP, Sattler FR, Forthal DN, Kemper CA, Dunne MW, et al (California Collaborative Treatment Group). Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996;335:392-398
293. Baker RL, Morris SA. Clarithromycin prophylaxis against MAC in AIDS [abstract]. Program Abstr Intersci Conf Antimicrob Agents Chemother 1994;34:210
294. Griffith DE, Brown BA, Girard WM, Murphy DT, Wallace RJ Jr. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. Clin Infect Dis 1996:23:983-989
295. Brown BA, Griffith DE, Girard W, Levin J, Wallace RJ Jr. Relation ship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. Clin Infect Dis 1997:24:958-964
296. Wallace RJ, Griffith DE, Brown BA, Murphy D, Girard W, Cegielsky JP. Initial results of three times weekly azithromycin in treatment regimens of Mycobacterium avium-intracellulare (MAI) lung disease in non-AIDS [abstract]. In: Proceedings and Abstracts of the Third International Conference on Macrolides, Azalides, and Streptogramins: 1996 Jan 24-26; Lisbon (Portugal)
297. Butler T, Sridhar CB, Daga MK, Jani K, Pandit RB, Khakhria R, et al. Treatment of typhoid fever with azithromycin vs chloramphenicol in a randomized multicenter trial in India [abstract]. Program Abstr Intersci Conf Antimicrob Agents Chemother 1997:37:367
298. Kuschner RA, Trofa AF, Thomas RJ, Hoge CW, Pitarangsi C, Amato S, et al. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis 1995;21:536-541
299. Murphy GS Jr, Echeverria P, Jackson LR, Arness MK, LeBron C, Pitarangsi C. Ciprofloxacin- and azithromycin-resistant Campylobacter causing traveler's diarrhea in U.S. troops deployed to Thailand in 1994. Clin Infect Dis 1996:22:868-869
300. Khan WA, Seas C, Dhar U, Salam MA, Bennish ML. Treatment of shigellosis. V. Comparison of azithromycin and ciprofloxacin: a double-blind, randomized, controlled trial. Ann Intern Med 1997: 126:697-703
301. Shanks GD, Ragama OB, Aleman GM, Andersen SL, Gordon DM. Azithromycin prophylaxis prevents epidemic dysentery. Trans R Soc Trop Med Hyg 1996:90:316
302. Bailey RL, Arullendran P, Whittle HC, Mabey DC. Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet 1993:342:453-456
303. Dawson CR, Schachter J, Sallam S, Sheta A, Rubinstein RA, Washton H. A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clin Infect Dis 1997:24:363-368
304. Hulten K, Cars 0, Hjelm E, Engstrand L. In vitro activity of azithromycin against intracellular Helicobacter pylori. J Antimicrob Chemother 1996:37:483-489
305. Harrison JD, Jones JA, Morris DL. Azithromycin levels in plasma and . gastric tissue, juice and mucus. Enr J Clin Microbiol Infect Dis 1991:10:862-864
306. Bertoni G, Sassatelli R, Nigrisoli E, Tansini P, Bianchi G, Delia Casa G, et al. Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacfer-pylori: a controlled trial versus omeprazole plus amoxicillin. Am J Gastroenterol 1996:91:258-263
307. al-Assi MT, Genta RM, Karttunen TJ, Cole RA, Graham DY. Azithromycin triple therapy for Helicobacter pylori infection: azithromycin, tetracycline, and bismuth. Am J Gastroenterol 1995:90:403-405
308. Tursi A, Cammarota G, Montalto M, Papa A, Fedeli G, Gasbarrini G. The use of azithromycin in short-term low-dose triple therapies for Helicobacter pylori infection [letter]. Am J Gastroenterol 1996; 91:817-818
309. Pilotto A, Di Mario F, Franceschi M, Leandro G, Soffiati G, Scagnelli M, et al. Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers. Aliment Pharmacol Ther 1996;10:1021-1027
310. Caselli M, Ruina M, Fabbri P, Balhous W, Alvisi V. A comparative trial of short term therapy with omeprazole plus either afnoxycillin or azithromycin for Helicobacter pylori eradication [letter], J Antimicrob Chemother 1996;37:849-850
311. Caselli M, Trevisani L, Tursi A, Sartori S, Ruina M, Luzzi I, et al. Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1997;9:45-48
312. Johnson RC, Kodner C, Russell M, Girard D. In-vitro and in-vivo susceptibility of Borrelia burgdorferi to azithromycin. J Antimicrob Chemother 1990;25(Suppl A):33-38
313. Massarotti EM, Luger SW, Rahn DW, Messner RP, Wong JB, Johnson RC, et al. Treatment of early Lyme disease. Am J Med 1992;92:396-403
314. Strle F, Ruzic E, Cimperman J. Erythema migrans: comparison of treatment with azithromycin, doxycycline and phenoxymethyl-penicillin. J Antimicrob Chemother 1992:30:543-550
315. Weber K, Wilske B, Preac-Mursic V, Thurmayr R. Azithromycin versus penicillin V for the treatment of early Lyme borreliosis. Infection 1993:21:367-372
316. Luft BJ, Dattwyler RJ, Johnson RC, Luger SW, Bosler EM, Rahn DW, et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans: a double-blind, randomized, controlled trial. Ann Intern Med 1996:124:785-791
317. Strle F, Maraspin V, Lotric-Furlan S, Ruzic-Sabljic E, Cimperman J. Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans. Infection 1996:24:64-68
318. Girgis NI, Frenck RW, Sultan Y. Single dose azithromycin compared to a four dose rifampin regimen for the eradication of meningococcal nasopharyngeal carriage [abstract]. Program Abstr Intersci Conf Antimicrob Agents Chemother 1997:37:364
319. Gingras BA, Jensen JB. Activity of azithromycin (CP-62,993) and erythromycin against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro. Am J Trop Med Hyg 1992:47:378-382
320. Kuschner RA, Heppner DG, Andersen SL, Wellde BT, Hall T, Schneider l, et al. Azithromycin prophylaxis against a chloroquineresistant strain of Plasmodium falciparum [published erratum appears in Lancet 1994;344:69]. Lancet 1994;343:1396-1397
321. Andersen SL, Ager A, McGreevy P, Schuster BG, Wesche D, Kuschner R, et al. Activity of azithromycin as a blood schizonticide against rodent and human plasmodia in vivo. Am J Trop Med Hyg 1995:52:159-161
322. Taylor WRJ, Richie TL, Fryauff DF, Picarima H, Widjaja H, Murphy GF, et al. The tolerance to daily azithromycin malaria prophylaxis by adults in Irian Jaya, Indonesia [abstract]. Program Abstr Intersci Conf Antimicrob Agents Chemother 1997:37:379
323. Sadiq ST, Glasgow KW, Drakeley CJ, Muller O, Greenwood BM, Mabey DC, et al. Effects of azithromycin on malariometric indices in The Gambia. Lancet 1995:346:881-882
324. Taylor WR, Richie TL, Fryauff DJ, Picarima H, Ohrt C, Tang D, et al. Malaria prophylaxis using azithromycin: a double-blind, placebocontrolled trial in Irian Jaya, Indonesia. Clin Infect Dis 1999:28:74-81
325. Weiss LM, Wittner M, Wasserman S, Oz HS, Retsema J, Tanowitz HB. Efficacy of azithromycin for treating Babesia microti infection in the hamster model. J Infect Dis 1993:168:1289-1292
326. Wittner M, Lederman J, Tanowitz HB, Rosenbaum GS, Weiss LM. Atovaquone in the treatment of Babesia microti infections in hamsters. Am J Trop Med Hyg 1996;55:219-222
327. Cantin L, Chamberland S. In vitro evaluation of the activities of azithromycin alone and combined with pyrimethamine against Toxoplasma gondii. Antimicrob Agents Chemother 1993:37:1993-1996
328. Araujo FG, Guptill DR, Remington JS. Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii. Antimicrob Agents Chemother 1988;32:755-757
329. Dumas JL, Chang R, Mermillod B, Piguet PF, Comte R, Pechere JC. Evaluation of the efficacy of prolonged administration of azithromycin in a murine model of chronic toxoplasmosis. J Antimicrob Chemother 1994:34:111-118
330. Derouin F, Almadany R, Chau F, Rouveix B, Pocidalo JJ. Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis. Antimicrob Agents Chemother 1992; 36:997-1001
331. Saba J, Morlat P, Raffi F, Hazebroucq V, Joly V, Leport C, et al. Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS. Eur J Clin Microbiol Infect Dis 1993:12:853-856
332. Farthing C, Rendel M, Currie B, Seidlin M. Azithromycin for cerebral toxoplasmosis [letter] [published erratum appears in Lancet 1992; 339:1124]. Lancet 1992:339:437-438
333. Wiselka MJ, Read R, Finch RG. Response to oral and intravenous azithromycin in a patient with Toxoplasma encephalitis and AIDS. J Infect 1996:33:227-229
334. Hardy WD, Bozzette S, Safrin S, et al. Results from recent therapeutic trials for opportunistic infections from the United States. AIDS 1994;8:S15
335. Garcia-Diaz JB, Palau LA, Pankey GA. Mycobacterium abscessus infections treated with azithromycin [abstract]. Program Abstr Intersci Conf Antimicrob Agents Chemother 1997;37:366
336. Dupont C, Bougnoux ME, Turner L, Rouveix E, Dorra M. Microbiological findings about pulmonary cryptosporidiosis in two AIDS patients. J Clin Microbiol 1996;34:227-229
337. Hicks P, Zwiener RJ, Squires J, Saved V. Azithromycin therapy for Cryptosporidium parvum infection in four children infected with human immunodeficiency virus. J Pediatr 1996;129:297-300
338. Blanshard C, Shanson DC, Gazzard BG. Pilot studies of azithromycin, letrazuril and paromomycin in the treatment of cryptosporidiosis. Int J STD AIDS 1997;8:124-129
339. Guerra LG, Neira CJ, Boman D, Ho H, Casner PR, Zuckerman M, et al. Rapid response of AIDS-related bacillary angiomatosis to azithromycin. Clin Infect Dis 1993;17:264-266
340. Chia JK, Nakata MM, Lami JL, Park SS, Ding JC. Azithromycin for the treatment of cat-scratch disease. Clin Infect Dis 1998;26:193-194
341. Hoque S, Weir A, Ruck R, Cunningham J. Rhodococcus equi in CAPD-associated peritonitis treated with azithromycin. Nephrol Dial Transplant 1996:11:2340-2341
342. Mascelllno MT, lona E, Ponzo R, Mastroianni CM, Delia S. Infections due to Rhodococcus equi in three HIV-infected patients: microbiological findings and antibiotic susceptibility. Int J Clin Pharmacol Res 1994:14:157-163
343. Rouse MS, Steckelberg JM, Brandt CM, Patel R, Miro JM, Wilson WR. Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis. Antimicrob Agents Chemother 1997;41:1673-1676
344. Lonks JR, Medeiros AA. The growing threat of antibiotic-resistant Streptococcus pneumoniae. Med Clin North Am 1995 May;79:523535
345. Breiman RF, Butler JC, Tenover FC, Elliott JA, Facklam RR. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994;271:1831-1835
346. Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA 1997;278:901-904